|
CHRISTIAN ROHLFF, PHD
CHIEF EXECUTIVE OFFICER Dr Rohlff became Chief Executive of Oxford BioTherapeutics in 2004, after founding the company and acquiring key targeting technology, bioinformatics data and intellectual property. He brings more than 20 years of experience in the international biotechnology industry to OBT. Following his PhD in Pharmacology from Georgetown University, he held a number of positions at the US National Cancer Institute. Prior to joining OBT, he held a number of positions of increasing seniority with Oxford Glycosciences, and led the company’s partnerships in oncology with Pfizer, GSK, Bayer, Wyeth, Takeda, Oxford University and the FDA. |
|
ABDERRAHIM FANDI, MD, PHD
CHIEF MEDICAL OFFICER Dr Fandi is a docteur of Medecine and Medical Oncology at Paris University Rene Descart, Paris, France. Following his training in medical oncology, a Clinial Pharmacology Oncology degree from Paris VII Lariboisiere Saint-Louis, a PhD in Experimental Paediatrics at the University of Turin and three years in academic at the Phase I Program Unit at Institut Gustave Roussy, he joined the pharmaceutical industry in 1995 working for major companies including Sanofi, AstraZeneca, Bristol Myers Squibb and Novartis. More recently, he spent the past seven years at Celegene first as site head of the New Jersey site leading a large multidisciplinary clinical development team before moving to the European site in Switzerland in 2014 where he led Celgene's epigenetic program in combination with immune-oncology checkpoints in solid tumours. Dr Fandi brings a wealth of experience in Clinical Reseach and Development, and health authority interactions (including the FDA), to OBT, having led the development of several novel chemotherapy compounds and small molecules in solid tumours. Dr Fandi has authored over 100 peer-reviewed publications, including first author publications in the Journal of Clinical Oncology. |
|
SCOTT SANDLER
VICE PRESIDENT, FINANCE Mr Sandler brings over 20 years of financial experience in the biotechnology industry to OBT. Most recently, he was Senior Director at Hyperion Therapeutics, a pharmaceutical company focussed on therapies for orphan diseases. Previously, he has held financial roles at Ipsen, Nektar Therapeutics and Genentech. Mr. Sandler holds an BSE in engineering from Tufts University and an MBA from the University of Michigan. |
|
ROBERT BOYD, PhD
UK SITE HEAD & SCIENTIFIC DIRECTOR Dr Boyd brings more than 20 years' experience in therapeutic antibody target discovery to OBT. He joined OBT from the MRC Toxicology Unit where as a senior investigator he identified novel lymphoma targets. He was previously head of proteome biology at Oxford Glycosciences where he led its oncology target discovery team. Dr Boyd holds a PhD in Biochemistry from Sussex University and conducted post-doctoral research at the Royal Postgraduate Medical School and the Imperial Cancer Research Fund. |
|
MIKE ROGERS
INTERIM HR DIRECTOR Mr Rogers is a Strategic HR professional with a depth of experience gained over the past 20 years supporting the development of high performing organisations within a range of emerging life sciences and medical diagnostic businesses such as Oxford Asymmetry International (Evotec), Oxford Immunotec, Genzyme Therapeutics, and most recently Silence Therapeutics Plc in RNAi drug development. Mr Rogers has an MA in Economics from Edinburgh University and is a Member of the Chartered Institute of Personnel and Development. |